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Abstract
Background: Female survivors of childhood cancer treated with abdominal radiotherapy who manage to conceive are at risk
of delivering premature and low-birthweight offspring, but little is known about whether abdominal radiotherapy may also
be associated with additional complications during pregnancy and labor. We investigated the risk of developing pregnancy
and labor complications among female survivors of childhood cancer in the British Childhood Cancer Survivor Study (BCCSS).
Methods: Pregnancy and labor complications were identified by linking the BCCSS cohort (n¼17 980) to the Hospital Episode
Statistics (HES) for England. Relative risks (RRs) of pregnancy and labor complications were calculated by site of radiotherapy
treatment (none/abdominal/cranial/other) and other cancer-related factors using log-binomial regression. All statistical tests
were two-sided.
Results: A total of 2783 singleton pregnancies among 1712 female survivors of childhood cancer were identified in HES.
Wilms tumor survivors treated with abdominal radiotherapy were at threefold risk of hypertension complicating pregnancy
(relative risk ¼ 3.29, 95% confidence interval [CI] ¼ 2.29 to 4.71), while all survivors treated with abdominal radiotherapy were
at risk of gestational diabetes mellitus (RR¼3.35, 95% CI¼1.41 to 7.93) and anemia complicating pregnancy (RR¼2.10, 95%
CI¼1.27 to 3.46) compared with survivors treated without radiotherapy. Survivors treated without radiotherapy had similar
risks of pregnancy and labor complications as the general population, except survivors were more likely to opt for an elective
cesarean section (RR¼1.39, 95% CI¼1.16 to 1.70).
Conclusions: Treatment with abdominal radiotherapy increases the risk of developing hypertension complicating pregnancy
in Wilms tumor survivors, and diabetes mellitus and anemia complicating pregnancy in all survivors. These patients may
require extra vigilance during pregnancy.
Survival from childhood cancer has improved considerably over
the last few decades, and currently nearly 80% of children diag-
nosed with cancer survive at least five years (1). This dramatic
improvement in survival is mainly attributable to advances in
multimodality therapy with combination chemotherapy and
improved radiotherapy delivery. However, various studies have
shown that previous cancer treatment, particularly following
radiotherapy, increases the long-term risk of developing
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adverse health outcomes, including second primary cancer, car-
diovascular disease, infertility, and adverse pregnancy out-
comes (2,3).
Female survivors of childhood cancer who have been treated
with abdominal radiotherapy and who subsequently managed
to conceive are at risk of premature delivery and delivering low-
birthweight offspring (4–10). The exact mechanism underlying
this risk is not entirely clear, but it has been postulated that ex-
posure to abdominal irradiation increases myometrial fibrosis
and negatively affects vascular and/or muscular development
of the uterus (11,12). Although the risks of premature delivery
and delivering low-birthweight offspring in survivors of child-
hood cancer are well documented (4–10), it is unclear whether
previous treatment with abdominal radiotherapy for childhood
cancer may also be associated with additional complications
during pregnancy and labor. Green et al. (5,13) reported that fe-
male survivors of unilateral Wilms’ tumor treated with flank ir-
radiation are at risk of fetal malposition, early or threatened
labor, and developing hypertension complicating pregnancy,
but to the best of our knowledge, no other large-scale study has
investigated the risk of specific pregnancy and labor complica-
tions in women treated with abdominal radiotherapy for child-
hood cancer.
The principal aim of this study was to investigate the risks
of developing pregnancy and labor complications ascertained
through linkage with hospital electronic health records in fe-
male survivors treated with abdominal radiotherapy for child-
hood cancer.
Methods
British Childhood Cancer Survivor Study
The British Childhood Cancer Survivor Study is a large-scale
population-based cohort of 17 980 five-year survivors of child-
hood cancer who were diagnosed with cancer between age 0 to
14 years from 1940 to 1991 in Britain (14). The cohort was ascer-
tained through the National Registry of Childhood Tumours.
The BCCSS cohort was linked to the population-based Hospital
Episode Statistics (HES) for England—an electronic database
that records data on patients’ hospital admissions (inpatient),
outpatient appointments, and accident and emergency attend-
ances at National Health Service (NHS) or private hospitals (if
care was commissioned by the NHS). HES is managed by NHS
digital and developed as a system for hospitals to get paid for
administered patient care. For this study, the BCCSS cohort was
linked to the inpatient HES data set from April 1, 1997, to
December 31, 2012, by a third party (Northgate Solutions) using
NHS number, date of birth, and postcode. Approval to link the
BCCSS cohort to HES without prior individual patient consent
was obtained from the Confidentiality Advisory Group and the
National Research Ethics Service.
As HES only covers England, 2116 (11.8%) five-year survivors
who were alive and residing in Scotland or Wales were excluded
from analyses. Among the 6192 female survivors in the cohort
who were alive as of April 1, 1997, 5126 (82.8%) had at least one
recorded hospital admission in the HES inpatient data set.
The HES inpatient data set includes any records relating to
care given for births that took place in NHS hospitals. Although
home deliveries and births in private hospitals should be re-
corded in HES, practically few are (15), and hence these deliv-
eries were excluded (n¼ 35). Pregnancies that resulted in a
multiple birth (n¼ 85) were also excluded as the risk of
pregnancy and labor outcomes is likely to differ from singleton
births.
For comparisons with the general population, a random
sample of 25 000 deliveries was extracted from the entire
(anonymized) HES database (n¼ 8 821 531 deliveries). A sample
of 25 000 was decided upon because at that size the sample was
sufficiently large to provide ample statistical power, and, more-
over, larger samples (eg, n ¼ 100 000) resulted in similar results
(results not shown).
Pregnancy and Labor Complications
Pregnancy and labor complications were only evaluated if there
were at least 50 affected pregnancies. Medical conditions and
complications are recorded in HES using the International
Classification of Diseases (ICD), revision 10. Specifically, we inves-
tigated the risk of: hypertension complicating pregnancy (ICD-
10: O10-O11/O13-O16), gestational diabetes mellitus (O24.4), an-
emia complicating pregnancy (O99.0), malpresentation of fetus
(O32), maternal care due to uterine scar from previous surgery
(O34.2), fetal problems (O36), premature rupture of membranes
(ie, rupture of the amniotic sac; O42), prolonged pregnancy
(O48), abnormalities of forces of labor (O62), long labor (O63), ob-
structed labor due to malposition of fetus (O64), delivery compli-
cated by fetal stress (O68), umbilical cord complications (O69),
perineal laceration (O70), and postpartum hemorrhage (O72). In
addition, the likelihood of the delivery method being elective or
emergency cesarean and whether there were any high-risk
pregnancies that needed supervision (ICD-10: Z35) was also
evaluated. Adverse pregnancy outcomes evaluated in this study
included low-birthweight baby, preterm delivery, and stillbirth.
Statistical Analysis
A log-binomial regression model—with a population-averaged
generalized estimating equation modification accounting for
correlation between pregnancies of the same survivor—was
used to calculate relative risk (RR) estimates of pregnancy and
labor complications by type of childhood cancer, site of
radiotherapy treatment (none/cranial/abdominal/other), age at
childhood cancer, and calendar period of treatment (<1980/
1980–1984/1985–1991). Abdominal radiotherapy was defined as
any radiotherapy received for a tumor in the abdomen or pelvic
volume. All models included the potential confounders mater-
nal age and parity unless otherwise specified. Relative risks
were also calculated for Wilms tumor survivors as these would
have received some of the highest doses of abdominal irradi-
ation and also comprise a sufficiently large group to consider
separately. To determine whether survivors differed in their
risk of developing pregnancy and labor complications from the
general population independent of an effect of radiotherapy,
survivors treated without radiotherapy were chosen for com-
parisons with the general population.
Although the completeness of HES ascertainment increased
over calendar years, not all deliveries may have been recorded
within HES, particularly before 2002 (15,16). A recent exercise
whereby HES delivery records from 2002 to 2010 were linked
with the Office of National Statistics (ONS) birth registrations
found that 96.8% of all births recorded by ONS were also re-
corded in HES, suggesting that—at least for the period 2002 to
2010—the majority of deliveries are captured by HES (17). To as-
certain whether potential underreporting of deliveries and ad-
verse pregnancy and labor outcomes in the years 1997 to 2001
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could have potentially introduced bias, we conducted a sensitiv-
ity analysis by fitting HES calendar year (1997–2001 vs 2002–
2012) as an interaction term in our model. Such an interaction
term should detect whether there is statistically significant
variation in the risk of developing a specific pregnancy or labor
complication by HES calendar year.
For factors with multiple categories, a test for homogeneity
of the relative risks across the levels of the factor was also
performed, and Pheterogeneity was used to indicate the statistical
significance of the overall test. All analyses were performed
using Stata 14 (StataCorp, College Station, Texas) (18).
Statistical significance was defined at a two-sided P value of
less than .05.
Results
Cohort Characteristics
A total of 2783 singleton deliveries among 1712 female survivors
of childhood cancer were available for analysis (Table 1). The
mean maternal age at the delivery-related admission was 28.7
years (SD ¼ 5.4 years). The majority of recorded deliveries were
among survivors of leukemia (32.9%, n ¼ 915), central nervous
system tumor (12.1%, n ¼ 336), and Wilms tumor (11.6%, n ¼
322). In terms of site of radiotherapy treatment, 205 (12.0%) sur-
vivors had received abdominal radiotherapy (of whom 127,
62.0%, were Wilms tumor survivors), 543 (31.7%) had received
radiotherapy to the brain, 529 (30.9%) had not been treated with
any radiotherapy, and 146 (8.5%) had received radiotherapy to
sites other than the abdomen or brain.
Hypertension, Diabetes Mellitus, and Anemia
in Pregnancy
The relative risk of developing hypertension complicating preg-
nancy was substantially elevated among Wilms tumor sur-
vivors treated with abdominal radiotherapy (RR¼ 3.29, 95%
confidence interval [CI] ¼ 2.29 to 4.71) vs those treated without
radiotherapy (Table 2). Twenty-three point seven percent of all
Wilms tumor survivors treated with abdominal radiotherapy
experienced hypertension that complicated the pregnancy vs
only 7.1% of all survivors not treated with radiotherapy and
6.0% of women in the general population. Wilms tumor sur-
vivors not treated with abdominal radiotherapy were, however,
not at statistically significant risk of developing hypertension
complicating pregnancy (RR¼ 1.36, 95% CI¼ 0.68 to 2.71). Other
survivors (ie, non-Wilms tumor) treated with abdominal radio-
therapy were not at statistically significant risk either
(RR¼ 1.09, 95% CI¼ 0.52 to 2.28). Similar relative risks as re-
ported above were observed when excluding preexisting hyper-
tension (ICD10: O10-O11), that is, for gestational hypertension
only (Table 2).
Survivors treated with abdominal radiotherapy were at 3.35-
fold (95% CI¼ 1.41 to 7.93) risk of gestational diabetes mellitus
compared with survivors treated without radiotherapy
(Table 2), and this relative risk was increased for both Wilms
tumor (RR¼ 2.73, 95% CI¼ 1.00 to 7.62) and non-Wilms tumor
(RR¼ 4.27, 95% CI¼ 1.54 to 11.83) survivors. Overall, 4.9% of all
survivors treated with abdominal radiotherapy developed dia-
betes mellitus during pregnancy, whereas this was only 1.5% in
all survivors not treated with radiotherapy and 1.6% in the gen-
eral population.
The relative risk of having developed anemia that compli-
cates pregnancy was statistically significantly elevated among
survivors treated with abdominal radiotherapy compared with
survivors treated without radiotherapy (RR¼ 2.10, 95% CI¼ 1.27
to 3.46) and elevated for both Wilms (RR¼ 2.00, 95% CI¼ 1.13 to
3.57) and non-Wilms tumor (RR¼ 2.25, 95% CI¼ 1.13 to 4.49) sur-
vivors (Table 2). Eight point three percent of all survivors treated
with abdominal radiotherapy experienced a pregnancy that was
complicated by anemia, compared with 4.0% of survivors
treated without radiotherapy and 4.4% in the general
population.
Maternal Care for Known or Suspected Disorder
Prior treatment with radiotherapy did not affect the likelihood of
receiving specific maternal care for a known or suspected malpre-
sentation of the fetus (Pheterogeneity ¼ .96), a uterine scar from pre-
vious surgery (Pheterogeneity ¼ .14), fetal problems such as poor fetal
growth (Pheterogeneity ¼ .66), or a prolonged pregnancy (Pheterogeneity
¼ .58) (Table 3). Previous treatment with radiotherapy to the brain
was associated with a small increased risk of premature rupture
of the membranes (RR¼ 1.49, 95% CI¼ 1.07 to 2.08).
Complications of Labor and Delivery
No statistically significant associations could be detected be-
tween any of the factors under study and the labor complica-
tions: abnormalities of forces of labor, long labor, obstructed
labor, umbilical cord complications, delivery complicated by
fetal stress (except for Wilms tumor survivors having a reduced
risk of a delivery being complicated by fetal stress (RR¼ 0.73,
95% CI¼ 0.57 to 0.94) (Table 4)), perineal laceration, or postpar-
tum hemorrhage (Table 5).
Cesarean Delivery and Supervision High-Risk Pregnancy
Compared with the general population, survivors treated with-
out radiotherapy were 39% more likely to opt for an elective
cesarean (RR¼ 1.39, 95% CI¼ 1.16 to 1.70). Particularly survivors
of a bone tumor (RR¼ 1.52, 95% CI¼ 1.05 to 2.20) and those
treated with abdominal radiotherapy (RR¼ 1.46, 95% CI¼ 1.07 to
1.99) (Table 5) were more likely to opt for a cesarean. Survivors
treated longer ago were more likely to undergo an elective
cesarean than more recently treated survivors (22.3% before
1980 vs 12.7% in 1985 to 1991, Ptrend ¼ .004). The risk of an emer-
gency cesarean was not elevated among survivors compared
with the general population (P ¼ .21), although survivors of
Hodgkin lymphoma appeared to be at reduced risk (RR¼ 0.59,
95% CI¼ 0.36 to 0.97). Pregnancies in survivors treated with ab-
dominal radiotherapy were not identified as high-risk pregnan-
cies requiring greater supervision than pregnancies in survivors
treated without radiotherapy (RR¼ 1.04, 95% CI¼ 0.58 to 1.87).
Adverse Pregnancy Outcomes
Wilms tumor survivors treated with abdominal radiotherapy
were at threefold risk of delivering offspring with a low birth-
weight compared with survivors treated without radiotherapy
(RR¼ 2.85, 95% CI¼ 1.79 to 4.48) (Supplementary Table 1, avail-
able online). The RR for preterm delivery was also statistically
significantly increased for Wilms tumor survivors (RR¼ 1.89,
95% CI¼ 1.30 to 2.74). Only 19 hospital admissions were related
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to a stillbirth, and no stillbirths were recorded among women
treated with abdominal radiotherapy.
Sensitivity Analysis by HES Calendar Year
No statistically significant variation was found in the relative
risk of developing a pregnancy or labor complication by HES cal-
endar year (Supplementary Table 2, available online),
suggesting that if there was potential underreporting of any
pregnancy or labor outcomes before HES year 2002, the effect
would have been minimal.
Discussion
To our knowledge, this is the largest study investigating the
risks of pregnancy and labor complications in childhood cancer
Table 1. Characteristics of female survivors with at least one recorded delivery episode in Hospital Episode Statistics (HES; n¼ 1712) and single-
ton pregnancies of female survivors recorded in HES (n¼ 2783)
Characteristic
Individuals
(n¼ 1712)
No. (%)
Pregnancies
(n¼ 2783)
No. (%)
Excluded pregnancies
(n¼ 120)*
No. (%)
Type of childhood cancer
Leukemia 546 (31.9) 915 (32.9) 32 (26.7)
Hodgkin lymphoma 93 (5.4) 153 (5.5) 11 (9.2)
Non-Hodgkin lymphoma 69 (4.0) 111 (4.0) 5 (4.2)
CNS tumor 218 (12.7) 336 (12.1) 19 (15.8)
Neuroblastoma 85 (5.0) 135 (4.9) 5 (4.2)
NH-retinoblastoma 89 (5.2) 143 (5.1) 3 (2.5)
H-retinoblastoma 35 (2.0) 58 (2.1) 5 (4.2)
Wilms tumor 199 (11.6) 322 (11.6) 14 (11.7)
Bone tumor 92 (5.4) 145 (5.2) 5 (4.2)
Soft-tissue sarcoma 112 (6.5) 185 (6.6) 6 (5.0)
Other 174 (10.2) 280 (10.1) 15 (12.5)
Type of radiotherapy
None 529 (30.9) 860 (30.9) 44 (36.7)
Brain 543 (31.7) 901 (32.4) 29 (24.2)
Other (nonbrain/abdominal) 146 (8.5) 231 (8.3) 12 (10.0)
Abdominal 205 (12.0) 326 (11.7) 9 (7.5)
Abdominal after:
Wilms tumor 127 (7.4) 207 (7.4) 3 (2.5)
Hodgkin lymphoma 19 (1.1) 30 (1.1) 2 (1.7)
Soft-tissue sarcoma 16 (0.9) 24 (0.9) 1 (0.8)
Bone tumor 15 (0.9) 23 (0.8) 1 (0.8)
Non-Hodgkin lymphoma 9 (0.5) 15 (0.5) 1 (0.8)
Neuroblastoma 7 (0.4) 10 (0.4) 0 (0.0)
Other 12 (0.7) 17 (0.6) 1 (0.8)
Unknown 289 (16.9) 465 (16.7) 26 (21.7)
Wilms tumor
No radiotherapy 59 (3.4) 96 (3.4) 4 (3.3)
Abdominal radiotherapy 127 (7.4) 207 (7.4) 3 (2.5)
Unknown 13 (0.8) 19 (0.7) 7 (5.8)
Age at childhood cancer diagnosis, y
0–4 802 (46.8) 1315 (47.3) 39 (32.5)
5–9 481 (28.1) 781 (28.1) 49 (40.8)
10–14 429 (25.1) 687 (24.7) 32 (26.7)
Calendar year of childhood cancer
1955–1969 78 (4.6) 102 (3.7) 3 (2.5)
1970–1974 175 (10.2) 246 (8.8) 13 (10.8)
1975–1979 308 (18.0) 500 (18.0) 21 (17.5)
1980–1984 465 (27.2) 809 (29.1) 42 (35.0)
1985–1991 686 (40.1) 1126 (40.5) 41 (34.2)
Maternal age, y
<18 32 (1.9)† 33 (1.2) 0 (0.0)
18–24 467 (27.3)† 636 (22.9) 29 (24.2)
25–29 532 (31.1)† 873 (31.4) 38 (31.7)
30–34 457 (26.7)† 818 (29.4) 33 (27.5)
35 224 (13.1)† 423 (15.2) 20 (16.7)
*Home deliveries and births in private hospitals (n¼ 35), as well as pregnancies that resulted in a multiple birth (n¼85), were excluded. CNS ¼ central nervous system;
H ¼ heritable; HES ¼ Hospital Episode Statistics; NH ¼ nonheritable.
†Relates to first recorded delivery episode.
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survivors. This study shows that treatment with abdominal
radiotherapy increases the risk of developing hypertension
complicating pregnancy in Wilms tumor survivors, as well as
diabetes mellitus and anemia complicating pregnancy in all
survivors. In addition, female survivors as a whole are more
likely to opt for an elective cesarean than the general popula-
tion. Our results of increased risks of preterm delivery and
babies born with low birthweight among female survivors of
childhood cancer treated with abdominal radiotherapy concur
with previously reported data (4–10).
In this study, hypertensive disorders complicated 23.7% of
all pregnancies among Wilms tumor survivors treated with
abdomino-pelvic radiotherapy. Consistent with these findings,
Green et al. (13) reported that 23.7% of all pregnancies among
Wilms tumor survivors treated with irradiation were compli-
cated by hypertension. There is a possibility that the risk of
hypertension complicating pregnancy may be related to a previ-
ous nephrectomy rather than actual abdominal radiotherapy;
however, because the vast majority of Wilms tumor survivors
would have undergone a nephrectomy (19,20), the risks should
then, in theory, also be increased among those Wilms tumor
survivors not treated with radiotherapy. However, this was not
supported by our data—only 9.4% of Wilms tumor survivors not
treated with abdominal radiotherapy developed hypertension
complicating pregnancy; not statistically significantly different
than that observed in the general population (6.0%) or than
other survivors not treated with radiotherapy (7.1%).
The exact biological mechanism explaining the risk of
hypertension and anemia complicating pregnancy after abdom-
inal radiotherapy is poorly understood. Hypertension, anemia,
and varying degrees of chronic glomerular impairment are well
documented features of chronic radiation-induced renal injury,
which may also reduce a survivor’s reserve against future renal
stresses. Statistically significant glomerular impairment has
been reported in 25% to 56% of children receiving renal doses of
12 to 24 Gy (21). It is plausible that hypertension and anemia
may be recognized for the first time during pregnancy in some
female survivors with less severe degrees of chronic radiation-
induced renal damage as a result of the greater physiological
stresses and increased medical surveillance during pregnancy.
To our knowledge, this is the first study to report an elevated
risk of developing diabetes in pregnancy among survivors
treated with abdominal radiotherapy. A linked cancer-birth
registry analysis from four US centers (8) showed in an explora-
tory analysis that female bone cancer survivors were at risk of
diabetes during pregnancy (RR¼ 4.92, 95% CI ¼ 1.60 to 15.13), but
this was based on small observed numbers. Other studies have
found that survivors of childhood cancer treated with abdom-
inal radiation are at risk of developing diabetes (22–25), but not
specifically during pregnancy. The mechanism for developing
diabetes mellitus is unclear but may relate to a radiation-
induced effect on the pancreas, perhaps causing inflammation
and fibrosis, which may reduce subsequent insulin secretion
from the islet cells.
In this study, survivors were more likely to opt for an elect-
ive cesarean than the general population. In a recent smaller
study, Melin et al. (26) observed a 50% increased odds among
456 survivors of childhood cancer for undergoing a cesarean de-
livery compared with siblings which is consistent with our find-
ings. It is not clear why survivors are more likely to opt for an
elective cesarean, but it could be indicative of the obstetrician
aiming to reduce any theoretical risk that a vaginal delivery
might have. For example, survivors previously exposed to treat-
ment modalities known to be associated with cardiomyopathy
(eg, chest irradiation and high-dose cumulative doses of anthra-
cycline) (27) might have opted for a cesarean delivery to de-
crease the potential risk relating to cardiomyopathy during
labor and puerperium.
Several potential limitations should be considered. First,
large-scale linkage exercises may suffer from inaccuracies with
regard to linking the correct patient to the corresponding health
records. However, because linkage of the BCCSS cohort with
HES was done using NHS number, date of birth, and postcode of
each patient, such inaccuracies in linkage are likely to be min-
imal. Lack of detailed treatment exposure, such as administered
chemotherapy and radiation treatment charts, did not allow for
conducting detailed dose-response analyses. However, we did
consider Wilms tumor survivors separately who, if treated with
radiotherapy, would have received one of the highest doses of
radiation to the abdomen of all childhood cancer survivors.
Evaluation of potential confounding of the association between
abdominal irradiation and specific pregnancy and labor compli-
cations by chemotherapy was also not possible. Investigation of
pregnancy and labor complications by detailed treatment ex-
posure would require a nested case-control study. Last, we ac-
knowledge that information on site of radiotherapy was
missing for 16.9% of all survivors.
A major strength of the current study is the population-
based design, which overcomes a variety of potential limita-
tions including the issue of selection bias related to ascertain-
ment of survivors of childhood cancer into the cohort. Hospital-
based studies are probably more likely to include those sur-
vivors who were treated more intensely, and any absolute risk
estimates of adverse late effects—including pregnancy
outcomes—are therefore more likely to be overestimated than
within a population-based study. It also provided us with the
opportunity to compare the risks of pregnancy and labor out-
comes with the general population in an entirely population-
based way. Additionally, record linkage of our cohort with the
population-based HES provides ascertainment of pregnancy
and labor outcomes in a systematic way, unlike studies that as-
certain adverse outcomes through either (postal) questionnaires
or hospital records, which may suffer from nonresponse or se-
lection bias, respectively.
It has previously been shown that uterine damage, mani-
fested by impaired growth and blood flow, is a likely conse-
quence of abdomino-pelvic irradiation (12,28,29) and that
uterine volume correlates with age at irradiation (30). Exposure
of the pelvis to radiation is associated with risk of miscarriage,
delivering prematurely, and low-birthweight offspring, and in
this study we have shown further evidence that there is a risk
of hypertension complicating pregnancy in Wilms tumor sur-
vivors, and diabetes mellitus and anemia complicating preg-
nancy in all survivors who have received abdominal
radiotherapy. Although survivors treated with abdominal radio-
therapy were more likely to opt for an elective cesarean, the
risks of specific complications during labor were not statistically
significantly increased, and there is thus no evidence base for
suggesting that an elective cesarean should be the optimum
mode of delivery in survivors of childhood cancer treated with
abdominal radiotherapy.
In conclusion, the results of this study into pregnancy and
labor complications among female survivors of childhood can-
cer show that treatment with abdominal radiotherapy increases
the risk of developing hypertension complicating pregnancy in
Wilms tumor survivors, and diabetes mellitus and anemia com-
plicating pregnancy in all survivors. These patients may require
extra vigilance during pregnancy.
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